DHEA Intravaginal Suppositories for Vaginal Atrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Postmenopausal women often experience vaginal dryness, dyspareunia, and sexual dysfunction due to the depletion of sex steroids, which existing hormone replacement therapies struggle to address effectively, particularly as they can lead to undesirable side effects such as increased breast cancer risk and cardiovascular events.
Innovation Solution
A method involving the administration of dehydroepiandrosterone (DHEA) or its precursors, combined with a selective estrogen receptor modulator (SERM) and Type 5 cGMP phosphodiesterase inhibitors, to increase sex steroid levels and improve vaginal health, minimizing side effects by targeting specific tissues and reducing systemic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone replacement therapy is administered to treat vaginal dryness in postmenopausal women, then vaginal health is improved, but the risk of breast cancer and cardiovascular events increases
Solution Approach 1:
The patent applies local quality by administering DHEA specifically to vaginal tissues through intravaginal suppositories, creating localized androgenic and estrogenic effects in the target area while avoiding systemic distribution. This localized approach treats vaginal atrophy effectively while minimizing exposure to other organs, thereby reducing the risk of breast cancer and cardiovascular events associated with systemic hormone replacement therapy.
Solution Approach 2:
The patent uses DHEA as an intermediary substance that can be converted locally into active androgens and estrogens within vaginal tissues. This intermediary approach allows the drug to exert therapeutic effects locally while being metabolized and inactivated systemically, reducing the harmful effects of direct estrogen administration while maintaining therapeutic benefits.
2Reliability
If sex steroid precursors are administered to improve vaginal health, then vaginal tissue health is improved, but systemic side effects may occur
Solution Approach 1:
The patent achieves local quality by using intravaginal administration of DHEA suppositories, which creates high concentrations of the drug specifically in vaginal tissues. The vaginal epithelium, lamina propria, and muscularis layers all benefit from localized DHEA conversion to androgens and estrogens, while systemic absorption is minimized, thereby reducing systemic side effects.
Solution Approach 2:
The patent employs self-service by utilizing the body's own enzymatic conversion of DHEA into active sex steroids within vaginal tissues. The vaginal cells themselves perform the conversion of DHEA to androgens and estrogens, creating a self-regulating system that produces therapeutic effects locally while the liver and other organs can metabolize and eliminate excess DHEA systemically, reducing the burden of systemic side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively treats vaginal dryness and improves sexual function by promoting androgenic and estrogenic effects on vaginal tissues, reducing inflammation, and enhancing vaginal wall thickness and collagen compactness, while minimizing systemic side effects.
Implementation Method 1
the androgens originating from the peripheral intracrine transformation of dehydroepiandrosterone (DHEA) into both androgens and estrogens
Implementation Method 2
administering a selective estrogen receptor modulator (SERM)
Implementation Method 3
Type 5 cGMP phosphodiesterase inhibitor may also be administered to improve sexual activity
Data Source
AI summary
Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance , in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure:is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.